Merck MRK announced that its phase III KEYLYNK-001 study, evaluating its blockbuster anti-PD-1 therapy Keytruda regimen in advanced epithelial ovarian cancer met the primary endpoint of ...

Merck's KEYLYNK-001 trial showed Keytruda and Lynparza improved progression-free survival in BRCA non-mutated ovarian cancer patients. In the waveLINE-007 trial, zilovertamab vedotin with R-CHP ...

Patients with BRCA-mutant ovarian cancer saw an improved progression-free survival with Lynparza, according to a recent study. There was a 70 percent reduction in the risk of progression or death with ...

Recentin plus Lynparza showed some clinical benefits but did not outperform standard chemotherapy in progression-free or overall survival. Side effects such as diarrhea, fatigue, and hypertension were ...

The Food and Drug Administration on Thursday granted expanded approval for AstraZeneca’s cancer drug Lynaparza. The agency first approved the drug in 2014 to treat advanced ovarian cancer in women who ...

The FDA-approved drug combination specifically targets low-grade serous ovarian cancer, which primarily affects younger women ...

On Monday, Merck & Co Inc (NYSE:MRK) announced topline data from the Phase 3 KEYLYNK-001 trial. The trial evaluating Keytruda (pembrolizumab) plus chemotherapy followed by maintenance with Lynparza ...